NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
OSL:NAVA - Euronext Oslo - NO0010205966 - Common Stock - Currency: NOK
Taking everything into account, NAVA scores 3 out of 10 in our fundamental rating. NAVA was compared to 53 industry peers in the Pharmaceuticals industry. The financial health of NAVA is average, but there are quite some concerns on its profitability. NAVA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
NAVA had negative earnings in the past year.
NAVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NAVA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of NAVA (-1.17%) is worse than 67.92% of its industry peers.
Looking at the Return On Equity, with a value of -2.53%, NAVA is doing worse than 67.92% of the companies in the same industry.
NAVA has a Return On Invested Capital (9.30%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for NAVA is below the industry average of 14.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROIC | 9.3% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 7.42%, NAVA is doing worse than 60.38% of the companies in the same industry.
NAVA's Operating Margin has improved in the last couple of years.
NAVA has a Gross Margin of 39.30%. This is in the lower half of the industry: NAVA underperforms 77.36% of its industry peers.
In the last couple of years the Gross Margin of NAVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
NAVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for NAVA has been increased compared to 1 year ago.
NAVA has more shares outstanding than it did 5 years ago.
NAVA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.96 indicates that NAVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
NAVA's Altman-Z score of 2.96 is in line compared to the rest of the industry. NAVA outperforms 45.28% of its industry peers.
NAVA has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as NAVA would need 3.29 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.29, NAVA is doing good in the industry, outperforming 60.38% of the companies in the same industry.
A Debt/Equity ratio of 0.37 indicates that NAVA is not too dependend on debt financing.
NAVA has a better Debt to Equity ratio (0.37) than 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 2.96 |
ROIC/WACC1.2
WACC7.73%
2.3 Liquidity
NAVA has a Current Ratio of 1.42. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
NAVA has a Current ratio (1.42) which is comparable to the rest of the industry.
NAVA has a Quick Ratio of 1.42. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NAVA (0.84) is worse than 60.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
The earnings per share for NAVA have decreased by -5.58% in the last year.
The Revenue has been growing slightly by 6.15% in the past year.
Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-353.86%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
3.2 Future
The Earnings Per Share is expected to grow by 30.84% on average over the next years. This is a very strong growth
NAVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.69% yearly.
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 9.65, the valuation of NAVA can be described as reasonable.
NAVA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NAVA is cheaper than 77.36% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 37.67. NAVA is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NAVA is valued a bit cheaper than 77.36% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, NAVA is valued a bit cheaper than the industry average as 69.81% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.99 | ||
| EV/EBITDA | 7.83 |
4.3 Compensation for Growth
NAVA's earnings are expected to grow with 40.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.37%
EPS Next 3Y40.99%
5. Dividend
5.1 Amount
No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (7/25/2025, 7:00:00 PM)
24.3
+0.1 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners32.09%
Inst Owner ChangeN/A
Ins Owners16.59%
Ins Owner ChangeN/A
Market Cap576.15M
Analysts82.86
Price Target36.11 (48.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.93%
Min Revenue beat(2)-17.93%
Max Revenue beat(2)-1.92%
Revenue beat(4)1
Avg Revenue beat(4)-6.45%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)3.23%
Revenue beat(8)3
Avg Revenue beat(8)-0.95%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.66%
PT rev (3m)4.12%
EPS NQ rev (1m)-1.66%
EPS NQ rev (3m)-1.66%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.65 | ||
| P/S | 1.08 | ||
| P/FCF | 15.99 | ||
| P/OCF | 14.64 | ||
| P/B | 2.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.83 |
EPS(TTM)-0.71
EYN/A
EPS(NY)2.52
Fwd EY10.37%
FCF(TTM)1.52
FCFY6.25%
OCF(TTM)1.66
OCFY6.83%
SpS22.41
BVpS9.14
TBVpS-1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROCE | 12.08% | ||
| ROIC | 9.3% | ||
| ROICexc | 11.12% | ||
| ROICexgc | 140.87% | ||
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% | ||
| FCFM | 6.78% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexcg growth 3Y90.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score6
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.01 | ||
| Cap/Depr | 8.24% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 5.07 | ||
| Cash Conversion | 49.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 2.96 |
F-Score6
WACC7.73%
ROIC/WACC1.2
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-353.86%
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
EBIT growth 1Y67.35%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y27.28%
EBIT Next 5Y26.96%
FCF growth 1Y189721%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y1706.01%
OCF growth 3YN/A
OCF growth 5Y25.36%